68Ga-PSMA-11 PET/CT在复发性激素敏感性前列腺癌(HSPC)中的应用:一项针对适合挽救治疗患者的前瞻性单中心研究
该前瞻性单中心研究纳入223例适合挽救治疗的激素敏感性前列腺癌患者,评估68Ga-PSMA-11 PET/CT检测复发部位的效能。结果显示总体阳性率39.9%(95%CI 33.5-46.7),34.5%患者临床管理发生改变;PSA、PSA倍增时间和T分期>3a为独立预测因素。
要点
- 68Ga-PSMA-11 PET/CT在适合挽救治疗的HSPC患者中总体阳性率为39.9%(95%CI 33.5-46.7%)。
- 34.5%的患者因PET/CT结果改变了临床管理。
- PSA、PSA倍增时间和T分期>3a是PET/CT阳性的独立预测因素(均p<0.03)。
核心结论
- 本研究证实68Ga-PSMA-11 PET/CT在适合挽救治疗的HSPC患者中检测前列腺癌部位总体表现良好,并在35.4%的病例中影响了治疗管理。
- 患者特征影响68Ga-PSMA-11 PET/CT阳性率,应考虑以减少假阴性扫描。
研究设计与样本
- 前瞻性单中心研究,连续纳入223例经组织学诊断、既往接受根治性治疗、证实生化复发(BCR)或生化持续(BCP)、激素敏感、至少6个月未接受雄激素剥夺治疗(ADT)且PSA<1.5 ng/mL或胆碱PET/CT阴性时任意PSA的患者。
- 临床管理改变由多学科肿瘤委员会定义。
- 临床情景分为:BCP(第1组,n=25)、首次BCR(第2组,n=121)、挽救治疗后BCR(第3组,n=77)。
主要发现
- 中位PSA为0.65 ng/mL(范围0.2-8.9),中位PSA倍增时间为9.3个月(范围0.4-144.6)。
- 96.9%的患者以根治性前列腺切除术作为主要治疗。
- 68Ga-PSMA-11 PET/CT阳性率为39.9%(95%CI 33.5-46.7%)。
- 疾病局限于盆腔者占23.3%,至少观察到一处远处病灶者占16.6%。
- 34.5%的患者观察到临床管理改变;PSA、PSA倍增时间和T分期>3a为独立预测因素(均p<0.03);68Ga-PSMA-11 PET/CT阳性率在第1组为56%,第2组为36.3%,第3组为40.3%。
临床怎么用
- 作者认为,患者特征影响68Ga-PSMA-11 PET/CT阳性率,应考虑以减少假阴性扫描。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The primary objective is to assess the efficacy of 68Ga-PSMA-11-PET/CT to detect recurrent location(s) in hormone-sensitive prostate cancer (PCa). Secondary objectives are (1) to evaluate changes in clinical management; (2) to determine which covariates independently predict positive scan; (3) to assess 68Ga-PSMA-11-PET/CT performance in different settings of PSA relapse. MATERIALS AND METHODS: Inclusion criteria include (1) histologically diagnosed PCa; (2) previous radical therapy; (3) proven biochemical recurrence (BCR) or biochemical persistence (BCP); (4) hormone-sensitive PCa (HSPC); (5) androgen deprivation therapy (ADT)-free for at least 6 months; (6) PSA < 1.5 ng/mL or any PSA in case of negative choline-PET/CT (n = 38). Changes in clinical management were defined by multidisciplinary tumour-board. Clinical settings were BCP (group-1, n = 25); first-time BCR (group-2, n = 121); BCR after salvage therapy (group-3, n = 77). RESULTS: Two hundred twenty-three (223) consecutive patients were enrolled: median PSA = 0.65 ng/mL (0.2-8.9) and median PSAdt = 9.3 months (0.4-144.6). 96.9% received RP as primary therapy. 68Ga-PSMA-11-PET/CT positivity rate was 39.9% (CI95% 33.5-46.7%). Disease confined to pelvis was detected in 23.3% of cases. At least one distant lesion was observed in 16.6% of cases. Secondary objectives are as follows: (1) changes in clinical management were observed in 34.5% of patients; (2) PSA, PSAdt and T stage > 3a were independent predictors (all p < 0.03); (3) 68Ga-PSMA-11-PET/CT positivity rate was 56% (in group 1, 36.3% in group 2, 40.3% in group 3. CONCLUSION: This study attested the overall good performance of 68Ga-PSMA-11-PET/CT to detect PCa locations in HSPC patients eligible for salvage therapy, influencing the therapy management in 35.4% of cases. Furthermore, patient characteristics are influencing factors of 68Ga-PSMA-11-PET/CT positivity rate and should be considered to reduce false negative scan.
引用
- Deandreis D, Guarneri A, Ceci F, et al. 68Ga-PSMA-11 PET/CT in recurrent hormone-sensitive prostate cancer (HSPC): a prospective single-centre study in patients eligible for salvage therapy. Eur J Nucl Med Mol Imaging. 2020. PMID: 32314028. doi:10.1007/s00259-020-04809-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。